“…Members of this species cause a significant proportion of acute respiratory tract infections in children [179,180]. Despite widespread pre-existing immunity, HAdV-C5 vectors are currently being used as vaccine platforms in many countries, principally against HIV [181,182], malaria [183,184,185], Ebola virus [186,187,188,189,190], influenza virus [191], tuberculosis [192,193], or in pre-clinical studies that are targeting Zika virus [194,195], Clostridium botulinum [196], type O foot-and-mouth disease virus [197], Middle East respiratory syndrome coronavirus [198,199], rabies virus [200,201], or Dengue virus [202]. In mice and NHPs, HAdV-C2 delivered antigens protected against Ebola virus [203].…”